Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1381809
This article is part of the Research Topic Surgical Management of Colorectal Pathologies View all 6 articles

Application of Multimodal Standardized Analgesia under the Concept of Enhanced Recovery after Surgery in Laparoscopic Radical Colorectal Cancer Surgery

Provisionally accepted
Lu Cao Lu Cao Le Zhang Le Zhang *Baoyu Chen Baoyu Chen *Likun Yan Likun Yan *Xianpeng Shi Xianpeng Shi *Lifei Tian Lifei Tian *
  • Shaanxi Provincial People's Hospital, Xi'an, China

The final, formatted version of the article will be published soon.

    Aims: To observe the efficacy and safety of multimodal standardized analgesia in patients undergoing laparoscopic radical colorectal cancer surgery. Methods: A prospective, double-blind, randomized study of patients who were admitted to our hospital between December 2020 and March 2022 with a diagnosis of colorectal cancer and who intended to undergo elective laparoscopic radical colorectal cancer surgery was conducted. The participants were randomly divided into two intervention groups, namely, a multimodal standardized analgesia group and a routine analgesia group. In both groups, the visual analogue scale (VAS) pain scores while resting at 6 h, 24 h, 48 h and 72 h and during movement at 24 h, 48 h and 72 h; the number of patient controlled intravenous analgesia (PCIA) pump button presses and postoperative recovery indicators within 3 days after surgery; the interleukin-6 (IL-6) and C-reactive protein (CRP) levels on the 1st and 4th days after surgery; and the incidence of postoperative adverse reactions and complications were recorded. Results: Compared with the control group, the multimodal standardized analgesia group had significantly lower VAS pain scores at different time points while resting and during movement (P<0.05), significantly fewer PCIA pump button presses during the first 3 postoperative days (P<0.05), and significantly lower IL-6 and CRP levels on the 1st postoperative day (P<0.05).There was no statistically significant difference in the time to out-of-bed activity, the time to first flatus, the IL-6 and CRP levels on the 4th postoperative day or the incidence of postoperative adverse reactions and complications between the two groups (P >0.05). Conclusion: For patients undergoing laparoscopic radical colorectal cancer surgery, multimodal standardized analgesia with ropivacaine combined with parecoxib sodium and a PCIA pump had a better analgesic effect, as it effectively inhibited early postoperative inflammatory reactions and promoted postoperative recovery and did not increase the incidence of adverse reactions and complications. Therefore, it is worthy of widespread clinical practice.

    Keywords: Laparoscopic radical colorectal cancer surgery, multimodal standardized analgesia, Enhanced recovery after surgery, Ropivacaine, parecoxib

    Received: 06 Feb 2024; Accepted: 07 May 2024.

    Copyright: © 2024 Cao, Zhang, Chen, Yan, Shi and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Le Zhang, Shaanxi Provincial People's Hospital, Xi'an, China
    Baoyu Chen, Shaanxi Provincial People's Hospital, Xi'an, China
    Likun Yan, Shaanxi Provincial People's Hospital, Xi'an, China
    Xianpeng Shi, Shaanxi Provincial People's Hospital, Xi'an, China
    Lifei Tian, Shaanxi Provincial People's Hospital, Xi'an, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.